AI English summary of an SEC filing — figures as filed
Bio-Techne TECHThe company said net sales for the quarter ended Q1 September 30, 2025 decreased 1% to $286.6 million. Organic revenue also decreased 1%, with foreign currency exchange having a favorable impact of 1% and businesses held-for-sale having an unfavorable impact of 1%.
Key points
AI summaryThe company said net sales for the quarter ended Q1 September 30, 2025 decreased 1% to $286.6 million. Organic revenue also decreased 1%, with foreign currency exchange having a favorable impact of 1% and businesses held-for-sale having an unfavorable impact of 1%.
The company said GAAP operating income for Q1 increased 19% to $47.7 million, and GAAP EPS was $0.24 compared to $0.21 in the prior year period. Adjusted operating income was $84.2 million, and adjusted operating margin was 29.9% compared to 29.0% in the prior year period.
The company said Protein Sciences segment net sales were $202.2 million, a decrease of 1%, and operating margin was 38.4% compared to 39.4% in the prior year period. The Diagnostics and Spatial Biology segment had net sales of $79.5 million, a decrease of 4%, and operating margin of 11.2% compared to 5.1% in the prior year period.
The company disclosed that net cash provided by operating activities for Q1 was $27,585 thousand compared to $63,889 thousand in the prior year period, and after net repayment of long-term debt of $(46,000) thousand, the long-term debt balance was $300,000 thousand. Cash and cash equivalents at the end of the period were $144,962 thousand.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q1 Net Sales $286.6 million, Down 1%
The company said net sales for the quarter ended Q1 September 30, 2025 decreased 1% to $286.6 million. Organic revenue also decreased 1%, with foreign currency exchange having a favorable impact of 1% and businesses held-for-sale having an unfavorable impact of 1%.
Source · Based on the filing body and exhibits
GAAP Operating Income $47.7 million, Adjusted Operating Margin 29.9%
The company said GAAP operating income for Q1 increased 19% to $47.7 million, and GAAP EPS was $0.24 compared to $0.21 in the prior year period. Adjusted operating income was $84.2 million, and adjusted operating margin was 29.9% compared to 29.0% in the prior year period.
Source · Based on the filing body and exhibits
Segment Net Sales and Operating Margins
The company said Protein Sciences segment net sales were $202.2 million, a decrease of 1%, and operating margin was 38.4% compared to 39.4% in the prior year period. The Diagnostics and Spatial Biology segment had net sales of $79.5 million, a decrease of 4%, and operating margin of 11.2% compared to 5.1% in the prior year period.
Source · Based on the filing body and exhibits
Q1 Operating Cash Flow and Debt Repayment
The company disclosed that net cash provided by operating activities for Q1 was $27,585 thousand compared to $63,889 thousand in the prior year period, and after net repayment of long-term debt of $(46,000) thousand, the long-term debt balance was $300,000 thousand. Cash and cash equivalents at the end of the period were $144,962 thousand.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…